For the first time, the FDA has endorsed molecular response as a possible new benchmark for evaluating the effectiveness of drug therapy and disease prognosis. The final Fact Sheet on Gleevec (imatinib mesylate) Prescribing Information Update approved new labeling changes for Gleevec, providing long-term efficacy results in newly diagnosed chronic phase patients with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML).
Go to Previous Page
Go to Next Page